甲状腺叶切除与颈清扫治疗N1b乳头状甲状腺癌
该倾向匹配队列研究在美国单中心纳入37例甲状腺叶切除(TL)和37例全甲状腺切除+放射性碘(TT+RAI)的N1b乳头状甲状腺癌患者,中位随访90-113个月,发现两组5年总生存、疾病特异性生存和无复发生存均无显著差异。结论提示,对经过严格选择、单侧肿瘤、低容量区域淋巴结转移且无临床结外侵犯的N1b患者,TL是有效安全的选择。
要点
- TL组与TT+RAI组5年OS、DSS和RFS均无显著差异。
- 本研究为单中心倾向匹配队列,样本量有限。
- TL可能适用于严格选择的N1b患者:单侧肿瘤、低容量淋巴结转移、无临床结外侵犯。
核心结论
- 在严格选择的N1b乳头状甲状腺癌患者中,甲状腺叶切除与全甲状腺切除+放射性碘在生存和复发结局上无重要差异。
研究设计与样本
- 美国单中心倾向匹配队列研究,纳入37例TL患者和37例TT+RAI患者,中位随访分别为113个月和90个月。
- 患者来自1986至2020年于纪念斯隆凯特琳癌症中心手术的成人N1b乳头状甲状腺癌数据库,研究于2024至2025年进行。
主要发现
- 5年总生存率TL组96.9%,TT+RAI组96.8%(HR 0.2;95%CI 0.03-1.58)。
- 5年疾病特异性生存率TL组96.7%,TT+RAI组100%。
- 5年无复发生存率TL组89.8%,TT+RAI组88.9%(HR 1.48;95%CI 0.39-5.58)。
- 生存率在5至10年间无变化。
临床怎么用
- 对严格选择、充分咨询的N1b乳头状甲状腺癌患者(单侧肿瘤、低容量区域淋巴结转移、无临床结外侵犯),甲状腺叶切除可作为有效安全的治疗选择。
局限性
- 单中心回顾性队列设计,样本量有限(TL组37例),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with papillary thyroid carcinoma (PTC) with lateral neck metastases (N1b) are usually treated with total thyroidectomy (TT), neck dissection, and adjuvant radioactive iodine (RAI). This philosophy comes with higher risks of complications and sequela than thyroid lobectomy (TL) and neck dissection alone. There are no prior studies on patients from the Western hemisphere that compare survival and recurrence outcomes between these groups. OBJECTIVE: To compare recurrence and survival outcomes in propensity-matched TL vs TT + RAI patients who presented with ipsilateral N1b PTC at a tertiary cancer center in the US. DESIGN, SETTING, AND PARTICIPANTS: This cohort propensity-matched study was conducted at a single US tertiary cancer center included 37 TL patients and 37 of 561 TT + RAI patients (after excluding patients with M1 disease), with a median (IQR) follow-up of 113 (58-241) and 90 (48-185) months, respectively. Adult patients with PTC with lateral neck node metastases (N1b) were identified from a thyroid cancer database. The study included patients undergoing surgery at Memorial Sloan Kettering Cancer Center from 1986 to 2020, inclusive, and the study was conducted from 2024 to 2025. MAIN OUTCOMES AND MEASURES: Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). RESULTS: Of 598 total individuals, the median (IQR) age was 41 (33-55) years, and 341 (57%) were female. The 5-year OS was 96.9% in the TL group and 96.8% in the TT + RAI group (hazard ratio [HR], 0.2; 95% CI, 0.03-1.58). The 5-year DSS was 96.7% in the TL group and 100% in the TT +RAI group. The 5-year RFS was 89.8% in the TL group and 88.9% in the TT + RAI group (HR, 1.48; 95% CI, 0.39-5.58). The survival rates did not change between 5 and 10 years. CONCLUSIONS AND RELEVANCE: This cohort study found that a select group of patients with N1b PTC treated with TL had no important difference in survival and recurrence outcomes compared with patients treated with TT + RAI. Therefore, TL is an effective and safe treatment option in carefully selected and appropriately counselled patients with N1b PTC with unilateral tumors and low-volume regional lymph node metastases without clinical extranodal extension.
引用
- Scholfield DW, Boe LA, Eagan A, et al. Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41411004. doi:10.1001/jamaoto.2025.4653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。